Medullary thyroid carcinoma

Clinical Oncology

Volumn 22, Issue 6, 2010, Pages 475-485

  Pacini, F ^a   Castagna, M G ^a   Cipri, C ^a   Schlumberger, M ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Calcitonin; Medullary thyroid cancer; MEN 2

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PENTAGASTRIN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; PROTEIN RET; TUMOR MARKER;

ARTICLE; ASPIRATION BIOPSY; BONE SCINTISCANNING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CLINICAL FEATURE; EXTERNAL BEAM RADIOTHERAPY; EXTRACELLULAR CALCIUM; FAMILIAL CANCER; GENE LOCATION; GENE MUTATION; GENETIC DISORDER; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HEMATOPOIETIC CELL; HETEROZYGOTE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA 2A; NECK DISSECTION; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROVOCATION TEST; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR RECURRENCE; BLOOD; CARCINOMA, MEDULLARY; GENETIC PREDISPOSITION; GENETICS; MUTATION; SIPPLE SYNDROME; THYROID NEOPLASMS; TREATMENT OUTCOME;

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77954757206     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.05.002     Document Type: Article

References (65)

1. Schlumberger M., Pacini F. Thyroid tumors 2006, Edition Nucleon, Paris, 313-340. Chapter 18.
2. Hedinger C., Williams E.D., Sobin L.H. Histological typing of thyroid tumours. International classification of tumours 1988, Springer-Verlag, Berlin. 2nd ed.
3. LiVolsi V.A. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 1997, 82:39-41.
4. Moley J.F., DeBenedetti M.K. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999, 229:880-887.
5. Scollo C., Baudin E., Travagli J.P., et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003, 88:2070-2075.
6. Przepiorka D., Baylin S.B., McBride O.W., Testa J.R., de Bustros A., Nelkin B.D. The human CT gene is located on the short arm of chromosome 11. Biochem Biophys Res Commun 1984, 120:493-499.
7. Pacini F., Fugazzola L., Basolo F., Elisei R., Pinchera A. Expression of calcitonin gene-related peptide in medullary thyroid cancer. J Endocrinol Invest 1992, 15:539-542.
8. Baloch Z., Carayon P., Conte-Devolx B., et al. Guidelines Committee, National Academy of Clinical Biochemistry Laboratory medicine practice guidelines. Calcitonin and RET proto-oncogene mesaurements. Thyroid 2003, 13:68-79.
9. Motté P., Vauzelle P., Gardet P., et al. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies. Clin Chim Acta 1988, 174:35-54.
10. Mulligan L.M., Kwok J.B., Healey C.S., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363:458-460.
11. Hofstra R.M., Landsvater R.M., Ceccherini I., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367:375-376.
12. Mulligan L.M., Eng C., Healey C.S., et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994, 6:70-74.
13. Santoro M., Carlomagno F., Romano A., et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995, 267:381-383.
14. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996, 276:1575-1579.
15. Schuffenecker I., Ginet N., Goldgar D., et al. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. Am J Hum Genet 1997, 60:233-237.
16. American Thyroid Association Guidelines Task Force, Kloos R.T., Eng C., Evans D.B., et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612.
17. Uchino S., Noguchi S., Adachi M., et al. Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas. Jpn J Cancer Res 1998, 89:411-418.
18. Romei C., Elisei R., Pinchera A., et al. Somatic mutations of the RET proto-oncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996, 81:1619-1622.
19. Schilling T., Bürck J., Sinn H.P., et al. Prognostic value of codon 918 (ATG->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 2001, 95:62-66.
20. Elisei R., Cosci B., Romei C., et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008, 93:682-687.
21. Boi F., Maurelli I., Pinna G., et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:2115-2118.
22. Kudo T., Miyauchi A., Ito Y., Takamura Y., Amino N., Hirokawa M. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid 2007, 17:635-638.
23. Pacini F., Fontanelli M., Fugazzola L., et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994, 78:826-829.
24. Rieu M., Lame M.C., Richard A., et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol 1995, 42:453-460.
25. Hahm J.R., Lee M.S., Min Y.K., et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001, 11:73-80.
26. Niccoli P., Wion-Barbot N., Caron P., et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997, 82:338-341.
27. Vierhapper H., Raber W., Bieglmayer C., Kaserer K., Weinhäusl A., Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997, 82:1589-1593.
28. Bugalho M.J., Santos J.R., Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 2005, 91:56-60.
29. Elisei R., Bottici V., Luchetti F., et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004, 89:163-168.
30. Costante G., Meringolo D., Durante C., et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007, 92:450-455.
31. Gagel R.F., Jackson C.E., Block M.A., et al. Age-related probability of development of hereditary medullary thyroid carcinoma. J Pediatr 1982, 101:941-946.
32. Leboulleux S., Travagli J.P., Caillou B., et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer 2002, 94:44-50.
33. Vasen H.F., van der Feltz M., Raue F., et al. The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Arch Intern Med 1992, 152:1250-1252.
34. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86:5658-5671.
35. Bugalho M.J., Domingues R., Santos J.R., Catarino A.L., Sobrinho L. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 2007, 141:90-95.
36. Wiench M., Wygoda Z., Gubala E., et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 2001, 19:1374-1380.
37. Elisei R., Romei C., Cosci B., et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007, 92:4725-4729.
38. Gharib H., McConahey W.M., Tiegs R.D., et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc 1992, 67:934-940.
39. Stålberg P., Carling T. Familial parathyroid tumors: diagnosis and management. World J Surg 2009, 33:2234-2243.
40. Wells S.A., Farndon J.R., Dale J.K., Leight G.S., Dilley W.G. Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg 1980, 192:451-458.
41. Stepanas A.V., Samaan N.A., Hill C.S., Hickey R.C. Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer 1979, 43:825-837.
42. Fugazzola L., Pinchera A., Luchetti F., et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994, 9:21-24.
43. Machens A., Schneyer U., Holzhausen H.J., Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005, 90:2029-2034.
44. Franc S., Niccoli-Sire P., Cohen R., et al. French Medullary Study Group (GETC)Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin Endocrinol 2001, 55:403-409.
45. Laure Giraudet A., Al Ghulzan A., Aupérin A., et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008, 158:239-246.
46. Yen T.W., Shapiro S.E., Gagel R.F., Sherman S.I., Lee J.E., Evans D.B. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 2003, 134:890-899.
47. Koopmans K.P., de Groot J.W., Plukker J.T., et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008, 49:524-531.
48. Barbet J., Campion L., Kraeber-Bodéré F., Chatal J.F., GTE Study Group Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005, 90:6077-6084.
49. Dottorini M.E., Assi A., Sironi M., Sangalli G., Spreafico G., Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996, 77:1556-1565.
50. Kebebew E., Ituarte P.H., Siperstein A.E., Duh Q.Y., Clark O.H. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000, 88:1139-1148.
51. Modigliani E., Cohen R., Campos J.M., et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol 1998, 48:265-273.
52. Fromigué J., De Baere T., Baudin E., Dromain C., Leboulleux S., Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:2496-2499.
53. Isozaki T., Kiba T., Numata K., et al. Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. Intern Med 1999, 38:17-21.
54. Lorenz K., Brauckhoff M., Behrmann C., et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 2005, 138:986-993.
55. Chatal J.F., Campion L., Kraeber-Bodéré F., et al. French Endocrine Tumor GroupSurvival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006, 24:1705-1711.
56. Scherübl H., Raue F., Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 1990, 116:21-23.
57. Orlandi F., Caraci P., Berruti A., et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 1994, 5:763-765.
58. Wu L.T., Averbuch S.D., Ball D.W., de Bustros A., Baylin S.B., McGuire W.P. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994, 73:432-436.
59. Schlumberger M., Abdelmoumene N., Delisle M.J., Couette J.E. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 1995, 71:363-365.
60. Di Bartolomeo M., Bajetta E., Bochicchio A.M., et al. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Ann Oncol 1995, 6:77-79.
61. Petursson S.R. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 1988, 62:1899-1903.
62. Bajetta E., Rimassa L., Carnaghi C., et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998, 83:372-378.
63. Cohen E.E.W., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase ii study. J Clin Oncol 2008, 28:4708-4713.
64. Schlumberger M.J., Elisei R., Bastholt L., et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009, 27:3794-3801.
65. Kober F., Hermann M., Handler A., Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 2007, 25:14065.